Related Experiment Video

Updated: Mar 28, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.4K

Big Data for cardiology: novel discovery?

Viktor Mayer-Schönberger1

  • 1Oxford Internet Institute, University of Oxford, Oxford, UK viktor.ms@oii.ox.ac.uk.

European Heart Journal
|December 26, 2015
PubMed

Insights

Big Data is revolutionizing cardiology by transforming scientific discovery and clinical practice. Embracing this data requires significant professional and institutional changes for continued advancement in cardiovascular medicine.

Area of Science:

  • Cardiology
  • Medical Informatics
  • Data Science

Background:

  • Big Data presents a paradigm shift in cardiology, offering more than incremental improvements.
  • The increasing volume and complexity of health data necessitate new analytical approaches.

Purpose of the Study:

  • To examine the potential of comprehensive datasets for scientific discovery in cardiology.
  • To assess the impact of Big Data on the scientific method and its application in cardiovascular research and practice.

Main Methods:

  • Review of the implications of Big Data on scientific methodology.
  • Analysis of the potential consequences for research and clinical practice in cardiology.

Main Results:

  • Big Data fundamentally alters the discovery process in cardiology.
  • The integration of Big Data enhances the potential for novel insights and personalized medicine.

Conclusions:

  • Cardiology's future hinges on effectively leveraging Big Data.
  • Significant adaptations in research methods, professional structures, and institutions are essential for Big Data to thrive in cardiology.
Abstract

Keywords:
Big DataCausalityCorrelationDiscoveryEmpirical analysisScientific method

More Related Videos

Retrospective Cardiac Gating with A Prototype Small-Animal X-ray Computed Tomograph05:32

Retrospective Cardiac Gating with A Prototype Small-Animal X-ray Computed Tomograph

Published on: February 21, 2025

775
High-Resolution Cardiac Positron Emission Tomography/Computed Tomography for Small Animals11:09

High-Resolution Cardiac Positron Emission Tomography/Computed Tomography for Small Animals

Published on: December 16, 2022

4.5K

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.1K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
417
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
741
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
796
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
687